Hemorrhagic stroke is a serious complication during pregnancy and puerperium that has a substantial maternal mortality of 35% to 83%, contributing to more than 5% to 12% of all maternal deaths.^[@R1]^ Previous studies suggested that pregnancy and puerperium were associated with an increased risk of stroke.^[@R2][@R3][@R4]^ The rupture of cerebral aneurysm and arteriovenous malformation (AVM) were the main causes.^[@R5][@R6][@R7]^ In a prospective and population-based study, researchers found that pregnancy did not increase AVM bleed rates, but risk of intracranial hemorrhage was increased during the postpartum period.^[@R8]^ Some other studies also found that pregnancy did not increase the risk of hemorrhage from an AVM.^[@R9],[@R10]^ Recently, another study reported the rate of intracranial hemorrhage from AVM was 8.1% per pregnancy, higher than the annual hemorrhage rate of AVM in female patients^[@R11]^; however, this study had a limited sample size. Given the increasing number of reported cases of intracranial hemorrhage from AVM during pregnancy and puerperium, we undertook this study to assess whether the risk of AVM rupture is increased during pregnancy and 6 weeks after delivery.

METHODS {#s1}
=======

Study population. {#s1-1}
-----------------

Patients were selected from a prospectively collected database of 979 consecutive female patients with a confirmed angiographic or histologic diagnosis of an AVM referred to Beijing Tiantan Hospital from 1960 to 2010. The Beijing Tiantan Hospital served as the referral center for all pregnant women with cerebral AVM rupture in the region of Beijing.

Study design and data analysis. {#s1-2}
-------------------------------

We conducted a case-crossover design, using cases at previous time points as their own controls. In this design, the risk of cerebral AVM rupture during pregnancy and puerperium (exposure period) was compared with the risk excluding pregnancy and puerperium (the control period). In China, more than 99% of women choose to conceive a child between ages 18 and 40 years^[@R12]^; therefore, only patients with AVM rupture aged 18 to 40 years were used in the case-crossover design (n = 393), and the first 18 years of age were subtracted from the person-time at risk. For each patient, the person-time of exposure period was calculated from the first week of pregnancy to 6 weeks after pregnancy (10 months). The person-time excluding pregnancy and puerperium periods was estimated by subtracting the exposure period from the total person-time. For example, the total person-time at risk for a woman of 28 years who had 2 children was calculated as 28 − 18 years, the time of exposure period was 2 × 10 months, and the control period was (28 − 18) × 12 − 2 × 10 months.

To identify the occurrence of AVM rupture during pregnancy and puerperium, 2 neurosurgery residents reviewed the history of intracranial bleeding and clinical records for each case. In patients with AVM rupture during pregnancy or puerperium, we collected information on maternal age, parity, gestational age, and Glasgow Outcome Scale scores at admission, modes of delivery, treatment, and maternal and fetal outcome. Maternal outcome was categorized according to the 5-point Glasgow Outcome Scale. Fetal outcome was according to the Apgar score on delivery for 1-5-10 minutes: scores 3 and below are generally regarded as critically low, 4--6 fairly low, and 7--10 generally normal.

Recent studies have reported that AVM is a genetic disease^[@R13][@R14][@R16]^; therefore, patient-years of follow-up were calculated from birth until AVM obliteration. Annual hemorrhage rate was calculated as the ratio of the number of hemorrhages to total number of patient-years of follow-up. Using case-crossover analysis, the ratio of the observed frequency of hemorrhage in the exposure period to the frequency in the control period was used to calculate estimates of the odds ratio (OR). ORs and 95% confidence intervals (CIs) for association between pregnancy and the rupture of AVM were estimated using a Mantel-Haenszel estimator^[@R17]^ (SPSS software, version 16.0; SPSS Inc., Chicago, IL).

Standard protocol approvals, registrations, and patient consents. {#s1-3}
-----------------------------------------------------------------

This study received approval from the Beijing Tiantan Hospital Research Ethics Committee. Written informed consent was obtained from all participants or their guardians (for each patient, written informed consent was completed after admission).

RESULTS {#s2}
=======

Of a total of 979 patients (mean age 26.1 ± 12.4 years), 797 hemorrhages occurred during 25,578 patient-years of follow-up, yielding an annual hemorrhage rate of 3.11%. Of the 579 patients aged 18 to 40 years, 456 hemorrhages occurred during 16,367 patient-years of follow-up, yielding an annual hemorrhage rate of 2.78%, which is lower than the rate in other age groups (OR = 0.75, 95% CI 0.65--0.86, *p* \< 0.05). Overall, the annual bleeding rate of AVM decreased year by year in the female patients ([figure 1](#F1){ref-type="fig"}). The characteristics of all patients are shown in [table 1](#T1){ref-type="table"}, and the age distribution of all patients is shown in [figure 2](#F2){ref-type="fig"}.
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Patient characteristics
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There were 393 patients with AVM rupture between the ages of 18 and 40 years. Of them, 54 patients had previous bleeding, and 24 patients (6.1%) received AVM treatment before the first pregnancy, including surgical resection (n = 18), gamma knife (n = 4), and interventional therapy (n = 2). Twelve hemorrhages occurred in 12 patients over 452 pregnancies, yielding a hemorrhage rate of 2.65% per pregnancy or 3.32% per year. Among the remaining 381 patients, 441 hemorrhages occurred during 10,627 patient-years of follow-up, yielding an annual hemorrhage rate of 4.14%. The OR for rupture of AVM during pregnancy and puerperium in patients with AVM, compared with the period of time excluding pregnancy and puerperium, was 0.71 (95% CI 0.61--0.82).

Of the 12 patients with AVM rupture during pregnancy and puerperium, headache, vomiting, limb dysfunction, and altered consciousness were the main clinical manifestations. Eleven patients were in antepartum, including 6 in the second trimester and 5 in the third trimester. The mean gestation time was 26.3 ± 7.6 weeks (range 15 to 38 weeks). Only one patient had rupture of AVM in postpartum. There was no case in the first trimester or during delivery ([figure 3](#F3){ref-type="fig"}).

![Distribution of gestation weeks of the 12 patients with arteriovenous malformation rupture during pregnancy](NEUROLOGY2013557652FF3){#F3}

All patients received emergency CT brain scans and 9 patients underwent emergency digital subtraction angiography (DSA) examinations to confirm the cerebral AVMs. Two patients were confirmed by pathology after operation and one patient was previously diagnosed with a cerebral AVM by DSA. Eight patients had a gestation age of less than 35 weeks. Of them, 4 patients chose to continue pregnancy, 3 of them delivered a healthy baby by cesarean section weeks later, and one delivered a premature baby at 31 weeks; the other 4 patients chose abortion considering the potential biological effects of radiation exposure after extensive counseling.

All patients were managed by multidisciplinary care teams (neurosurgery, neurology, obstetrics and gynecology, pediatrics, intensive care). Nine patients received surgical interventions, including 6 (50%) emergency surgical clot evacuation and resections of AVM, one elective surgical resection of AVM 3 months after cesarean delivery, one decompressive craniotomy, and one gamma knife. There were 4 fetal deaths (4 abortions) and no maternal deaths in the surgical treatment group. Three patients were managed conservatively, 2 with Spetzler-Martin grade V or VI AVM and one with a grade III AVM with a small stable intracranial hemorrhage. Of those managed conservatively, one maternal death occurred. The characteristics of the 12 patients, location of the AVM, mode of delivery, treatment, and maternal and fetal outcome are summarized in [table 2](#T2){ref-type="table"}.
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Summary of the 12 patients with AVM rupture during pregnancy and puerperium
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DISCUSSION {#s3}
==========

In the present study, we did not find an increased risk of AVM rupture in patients aged 18 to 40 years, which were the prime childbearing ages in the Chinese population. The case-crossover analysis using the time of pregnancy and the puerperium as a trigger also did not reveal an increased risk of AVM rupture in patients aged 18 to 40 years. The annual rate of hemorrhage in these patients was similar to the rate reported by natural-history studies of untreated AVM.^[@R18][@R19][@R20]^ These findings show that pregnancy is not associated with an increased risk of intracranial AVM rupture. Therefore, based on our data, we would not advise against pregnancy in women with intracranial AVMs. However, the issues facing patients with a ruptured AVM in pregnancy remained challenging.

Several predictors of hemorrhage in patients with an untreated cerebral AVM have been established, including patient age, AVM location, and deep venous drainage.^[@R21]^ Recently, there is an increasing number of reported cases of AVM rupture during pregnancy and puerperium,^[@R1],[@R9][@R10][@R11],[@R22][@R23][@R24]^ and in some studies, it was assumed that pregnancy was a risk factor for AVM rupture. In an earlier study, researchers reviewed 113 young patients with intracranial stroke aged 15 to 45 years and found that pregnancy posed a risk for AVM rupture.^[@R23]^ However, another study did not find that the natural history of AVM was altered by pregnancy.^[@R24]^ A recent study reviewed 54 women with cerebral AVM and found 4 patients with hemorrhages that occurred over 62 pregnancies.^[@R11]^ The results revealed that the rate of AVM rupture during pregnancy was higher than the annual hemorrhage rate. However, an important limitation of these studies was the small sample size. In this study, we included a larger sample size and used a case-crossover design to analyze the risk of AVM rupture during pregnancy and puerperium. To our knowledge, cases act as their own controls in a case-crossover study design. Only patients having an event of interest were enrolled and their exposures were intermittent. Pregnancy and the puerperium are transient and the rupture of AVM is abrupt. Therefore, the exposure during pregnancy and the puerperium is a valid trigger that can be used in a case-crossover study.^[@R25]^

In this study, most patients presented with intracranial hemorrhages in the second and third gestational trimester, accounting for 91.6% of all the patients ([figure 3](#F3){ref-type="fig"}). No case of AVM rupture occurred in the first trimester or during delivery. Although we did not find an increased risk of AVM rupture during pregnancy and the puerperium, we found that the AVM rupture occurred more frequently in late gestational age. This may be correlated with the more extensive changes of hemodynamic parameters, coagulative function, and vessel wall in the third trimester of pregnancy.

Because of small samples and sparse data about the treatment of AVM rupture during pregnancy and puerperium, the management of these patients is very difficult and controversial. Timely and accurate diagnosis of intracranial AVM is of utmost importance. At present, DSA is the gold standard in diagnosing AVM and CT scan is the preferred method in diagnosing intracranial hemorrhage. However, fetal radiation exposure is the major concern when using these examinations. In our group, there were no cases of radiation-induced fetal malformation in patients who chose to continue pregnancy after CT and DSA examinations. Several studies have indicated that the effective radiation dose to the fetus during DSA was very small.^[@R26][@R27][@R28]^ Recent studies about radiation exposure and pregnancy also demonstrated that a brain CT can be performed with lead shielding of the abdomen and pelvis.^[@R29]^ Although the additional radiation dose to the fetus from CT and DSA under lead shielding might be small, especially during middle to late pregnancy, further studies with a high level of evidence are needed to confirm this.

At present, there is no Class I or II evidence to guide the treatment of intracranial AVM in women during pregnancy. The timing of surgical intervention is controversial.^[@R30]^ Dias and Sekhar^[@R1]^ reported that early surgical resection of AVM did not have a better outcome during pregnancy compared with conservative treatment. In this study, one maternal death was encountered in the 12 patients with AVM rupture during pregnancy (8.3% maternal mortality). This seemingly high maternal mortality was in keeping with other large AVM series that quoted approximately 10% risk of death with initial AVM rupture.^[@R24]^ No maternal death occurred in the 6 patients who received emergent surgical resections of AVM ([table 2](#T2){ref-type="table"}). However, emergency surgical resection of AVM is not the first choice for all patients. For patients with Spetzler-Martin grade V or VI,^[@R24]^ conservative treatment was preferred because of very high morbidity and mortality associated with operating on these lesions. According to our experience, for patients with grades I to IV AVM, urgent surgical evacuation of the intracranial hematoma and resection of AVM should be performed if signs of brain herniation occur. For patients of later pregnancy, surgical intervention can be performed after cesarean delivery. Furthermore, close collaboration among multidisciplinary teams including the departments of neurology, neurosurgery, obstetrics and anesthesiology, pediatrics, and intensive care has been important for the management of this group of patients.

A strength of this study is that it included a large sample size of female patients with intracranial AVM. We used a case-crossover design to compare the risk of rupture of AVM during pregnancy and puerperium with the risk excluding this period for the cohort of women aged 18 to 40 years. However, we are aware that the single-center retrospective design of this study is one of its limitations, and the study includes exclusively Chinese patients. Second, there might be some patients who had a bleed but were admitted to a different hospital or died before reaching our hospital; therefore, a case ascertainment bias may exist. Third, we did not include patients who might have received AVM resection before 18 years of age in the case-crossover analysis, and these patients would have lower risk of a bleed during pregnancy. In addition, we did not follow up the young patients who presented with hemorrhage before pregnancy to determine whether hemorrhage occurred again during a subsequent pregnancy, so the study cannot answer the question of whether one or more pregnancies increase the risk of AVM rupture. However, we believe that this would be a very small possibility because most patients would have surgical resection of the AVM before their next pregnancy.

Our data suggest that the risk of cerebral AVM rupture is not increased during pregnancy and the puerperium. Therefore, we would not advise against pregnancy in patients with intracranial AVM. However, we found that AVM rupture usually occurred in late gestational age; therefore, more attention should be provided to maintain relative hemodynamic stability in these patients during mid to late pregnancy. The issues facing patients with ruptured AVM in pregnancy remained challenging and required multidisciplinary management including neurosurgeons, obstetricians, pediatricians, and intensivists.
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